117 related articles for article (PubMed ID: 7579034)
1. Comments concerning 'The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis'.
Washington C; Davis SS
Biopharm Drug Dispos; 1995 Aug; 16(6):529-31. PubMed ID: 7579034
[No Abstract] [Full Text] [Related]
2. The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis.
Bouley M; Tod M; Chavanet P; Petitjean O
Biopharm Drug Dispos; 1994 Aug; 15(6):485-92. PubMed ID: 7993986
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B formulated in a lipid emulsion.
Cleary JD
Ann Pharmacother; 1996 Apr; 30(4):409-12. PubMed ID: 8729899
[No Abstract] [Full Text] [Related]
4. [Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
Blancard A; Monges P; Lacarelle B; Denis JP; Bongrand MC; Ragon CH; Gouin F
Pathol Biol (Paris); 1996 May; 44(5):384-8. PubMed ID: 8758481
[TBL] [Abstract][Full Text] [Related]
5. Plasma protein adsorption patterns on surfaces of Amphotericin B-containing fat emulsions.
Schmidt S; Müller RH
Int J Pharm; 2003 Mar; 254(1):3-5. PubMed ID: 12615399
[TBL] [Abstract][Full Text] [Related]
6. Precipitation of amphotericin B from i.v. fat emulsion.
Heide PE
Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
[No Abstract] [Full Text] [Related]
7. [Amphotericin B. Lipid complex versus liposomes. Which, why, when?].
Pahissa A
Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):1-3. PubMed ID: 9147499
[No Abstract] [Full Text] [Related]
8. Amphotericin B intralipid formulation: stability and particle size.
Ranchère JY; Latour JF; Fuhrmann C; Lagallarde C; Loreuil F
J Antimicrob Chemother; 1996 Jun; 37(6):1165-9. PubMed ID: 8836819
[TBL] [Abstract][Full Text] [Related]
9. Design of amphotericin B oral formulation for antifungal therapy.
Liu M; Chen M; Yang Z
Drug Deliv; 2017 Nov; 24(1):1-9. PubMed ID: 28155335
[TBL] [Abstract][Full Text] [Related]
10. Antifungal penetration into normal rabbit nucleus pulposus.
Conaughty JM; Khurana S; Banovac K; Martinez OV; Eismont FJ
Spine (Phila Pa 1976); 2004 Jul; 29(14):E289-93. PubMed ID: 15247589
[TBL] [Abstract][Full Text] [Related]
11. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
[TBL] [Abstract][Full Text] [Related]
12. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
[TBL] [Abstract][Full Text] [Related]
13. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
17. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
18. Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B.
Hussain A; Samad A; Singh SK; Ahsan MN; Faruk A; Ahmed FJ
Drug Dev Ind Pharm; 2015 May; 41(5):780-90. PubMed ID: 24654936
[TBL] [Abstract][Full Text] [Related]
19. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
20. Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient.
Nicol AJ; Cassidy MJ; Michalowsky K; Kahn D
Nephron; 1996; 73(2):312-3. PubMed ID: 8773363
[No Abstract] [Full Text] [Related]
[Next] [New Search]
